Pharmacoeconomics Status in Asia and an Emerging Hub in the Indo-Pak

被引：0

作者：

Sadia, Halima ^{[1
]}

Rehman, Hina ^{[2
]}

Naveed, Safila ^{[3
]}

机构：

[1] Jinnah Univ Women, Fac Pharm, Dept Pharm Practice, Nazimabad 5C, Karachi 74600, Sindh, Pakistan

[2] Jinnah Sindh Med Univ, Fac Pharm, Dept Pharm Practice, Rafiqui Shaheed Rd, Karachi, Pakistan

[3] Jinnah Univ Women, Fac Pharm, Dept Pharmaceut Chem, Nazimabad 5C, Karachi, Pakistan

来源：

INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH | 2019年 / 53卷 / 03期

关键词：

Asia; Development; India; Pakistan; Pharmacoeconomics; Opportunities; HEALTH TECHNOLOGY-ASSESSMENT; PHARMACEUTICAL-INDUSTRY; DRUG DEVELOPMENT; COST; CARE; DECISION; QUALITY;

D O I：

10.5530/ijper.53.3.71

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

Objective: A review has been carried out to understand pharmacoeconomics and its development in the Asian region. Findings: Pharmacoeconomics is a subset of health economics which applies the methodologies and principles of health economics in clinical decision making. Currently, a number of countries around the globe have implemented pharmacoeconomics in their health care systems. However, the development of pharmacoeconomics in the Asia is very debatable. With countries like South Korea, Japan, China and Thailand where health economics is not only being implemented but is also progressing very rapidly, the southern part of Asia specifically India and Pakistan are far behind. Summary: Pharmacoecomics is in very infancy in the South Asia especially in India and Pakistan. It is the need of the hour to improve the practice and development of new pharmacoeconomics guidelines to meet up the standards of the remaining world.

引用

页码：376 / 381

页数：6

共 50 条

[11] Laparoscopic versus open colorectal surgery - Cost-benefit analysis in a single-center randomized trial
Braga, M
Vignali, A
Zuliani, W
Frasson, M
Di Serio, C
Di Carlo, V
[J]. ANNALS OF SURGERY, 2005, 242 (06) : 890 - 896
[12] Economic note - Cost of illness studies
Byford, S
Torgerson, DJ
Raftery, J
[J]. BRITISH MEDICAL JOURNAL, 2000, 320 (7245) : 1335 - 1335
[13] Health technology assessment development in China
Chen, Yingyao
Banta, David
Tang, Zhiliu
[J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2009, 25 : 202 - 209
[14] Cost-Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B
Dakin, Helen
Bentley, Anthony
Dusheiko, Geoff
[J]. VALUE IN HEALTH, 2010, 13 (08) : 922 - 933
[15] A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit
Dasta, Joseph F.
Kane-Gill, Sandra L.
Pencina, Michael
Shehabi, Yahya
Bokesch, Paula M.
Wisernandle, Wayne
Riker, Richard R.
[J]. CRITICAL CARE MEDICINE, 2010, 38 (02) : 497 - 503
[16] Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, Joseph A.
Grabowski, Henry G.
Hansen, Ronald W.
[J]. JOURNAL OF HEALTH ECONOMICS, 2016, 47 : 20 - 33
[17] What is next for pharmacoeconomics and outcomes research in Asia?
Doherty, J
Kamae, I
Lee, KKC
Li, H
Li, SC
Liu, GG
Tarn, YH
Yang, BM
[J]. VALUE IN HEALTH, 2004, 7 (02) : 118 - 132
[18] Use of pharmacoeconomics information - Report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making
Drummond, M
Brown, R
Fendrick, AM
Fullerton, P
Neumann, P
Taylor, R
Barbieri, M
[J]. VALUE IN HEALTH, 2003, 6 (04) : 407 - 416
[19] Drummond M, 2015, METHODS EC EVALUATIO
[20] Duenas A, 2013, ENCY BEHAV MED, P516

← 1 2 3 4 5 →